Celltrion has seen denied a bid for a preliminary injunction that would block the potential sale of its Omlyclo (omalizumab) biosimilar to Novartis/Genentech’s Xolair in many European countries, after the Düsseldorf local division of the Unified Patent Court ruled against the originators.
Presiding judge Ronny Thomas, supported by Bérénice Thom acting as judge-rapporteur and two others, denied Novartis and Genentech’s request that Celltrion cease and desist its activities around
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?